---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-009286"
form_type: "8-K"
ticker: "CING"
cik: "0001862150"
company_name: "Cingulate Inc."
filed_at: "2025-05-08T23:59:59+00:00"
generated_at: "2026-05-22T05:35:28.907990+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Cingulate Q1 net loss $3.8M, cash $9.5M; NDA submission for CTx-1301 on track mid-2025

## Summary
- Net loss of $3.8M ($1.04 per share) for Q1 2025, compared to $3.0M in Q1 2024.
- Cash and equivalents $9.5M at March 31, 2025; cash runway into Q4 2025 beyond NDA submission.
- Pre-NDA meeting with FDA completed April 2, 2025; NDA submission for CTx-1301 targeted mid-2025.
- Received $3M non-dilutive grant from private foundation to accelerate CTx-2103 (buspirone) anxiety asset.
- Working capital $4.9M at Q1 end, down from $7.7M at Dec 31, 2024.

## SEC filing metadata
- accession: 0001641172-25-009286
- form_type: 8-K
- ticker: CING
- cik: 0001862150
- company_name: Cingulate Inc.
- filed_at: 2025-05-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1862150/000164117225009286/0001641172-25-009286-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1862150/000164117225009286/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-009286
- JSON: https://secwatch.observer/filing/0001641172-25-009286.json
- Plain text: https://secwatch.observer/filing/0001641172-25-009286.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.